- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07277231
Een onderzoek naar Sonrotoclax (BGB-11417) plus Zanubrutinib (BGB-3111) vergeleken met Venetoclax plus Acalabrutinib bij volwassenen met voorheen onbehandeld chronische lymfatische leukemie
Een fase 3, open-label, gerandomiseerde studie van Sonrotoclax (BGB-11417) plus Zanubrutinib (BGB-3111) vergeleken met Venetoclax plus Acalabrutinib bij patiënten met eerder onbehandeld chronische lymfatische leukemie
The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocytic leukemia (CLL).
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Study Director
- Telefoonnummer: 8778285568
- E-mail: clinicaltrials@beonemed.com
Studie Locaties
-
-
New South Wales
-
Blacktown, New South Wales, Australië, NSW 2148
- Werving
- Blacktown Cancer and Haematology Centre
-
Concord, New South Wales, Australië, NSW 2139
- Werving
- Concord Repatriation General Hospital
-
St Leonards, New South Wales, Australië, NSW 2065
- Werving
- Genesiscare North Shore
-
-
Queensland
-
Woolloongabba, Queensland, Australië, QLD 4102
- Werving
- Princess Alexandra Hospital
-
-
Victoria
-
Clayton, Victoria, Australië, VIC 3168
- Werving
- Monash Health
-
Heidelberg, Victoria, Australië, VIC 3084
- Werving
- Austin Health
-
Malvern, Victoria, Australië, VIC 3144
- Werving
- Cabrini Hospital Malvern
-
Melbourne, Victoria, Australië, VIC 3004
- Werving
- The Alfred Hospital
-
-
-
-
-
Brasília, Brazilië, 70390140
- Werving
- Instituto Dor de Pesquisa E Ensino Distrito Federal
-
Porto Alegre, Brazilië, 90110-270
- Werving
- Centro Gaucho Integrado de Oncologia Hospital Mae de Deus
-
Salvador, Brazilië, 41950-640
- Werving
- Ensino E Terapia de Inovacao Clinica Amo Etica
-
São Paulo, Brazilië, 05652-900
- Werving
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
-
São Paulo, Brazilië, 01401-004
- Werving
- Instituto Dor de Pesquisa E Ensino Sao Paulo
-
-
-
-
British Columbia
-
Victoria, British Columbia, Canada, V8R 6V5
- Werving
- Bc Cancer Victoria
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V 5C2
- Werving
- Juravinski Cancer Centre
-
-
Quebec
-
Montreal, Quebec, Canada, QC H3t 1E2
- Werving
- Jewish General Hospital
-
Montreal, Quebec, Canada, H4J 1C5
- Werving
- Ciusss Nim Hscm
-
Québec, Quebec, Canada, G1J 1Z4
- Werving
- Chu de Quebec Universite Laval, Hopital de Lenfant Jesus, Centre Integre de Cancerologie (Cic)
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Werving
- Ciusss de Lestrie Chus
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100730
- Werving
- Peking Union Medical College Hospital
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, China, 630014
- Werving
- The First Affiliated Hospital of Chongqing Medical University
-
-
Fujian
-
Fuzhou, Fujian, China, 350005
- Werving
- The First Affiliated Hospital of Fujian Medical University
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510555
- Werving
- Sun Yat Sen University Cancer Center Huangpu Branch
-
Guangzhou, Guangdong, China, 510000
- Actief, niet wervend
- Zhujiang Hospital of Southern Medical University
-
-
Guangxi
-
Nanning, Guangxi, China, 530021
- Werving
- The First Affiliated Hospital of Guangxi Medical University
-
-
Guizhou
-
Guiyang, Guizhou, China, 550002
- Werving
- Guizhou Provincial Peoples Hospital
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150000
- Werving
- Harbin Medical University Cancer Hospital
-
-
Henan
-
Zhengzhou, Henan, China, 450000
- Werving
- Henan Cancer Hospital
-
-
Hunan
-
Changsha, Hunan, China, 410011
- Werving
- The Second Xiangya Hospital of Central South University
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Werving
- Jiangsu Province Hospital
-
Nantong, Jiangsu, China, 201203
- Werving
- Affiliated Hospital of Nantong University
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330006
- Werving
- The Second Affiliated Hospital of Nanchang University
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710004
- Werving
- The Second Affiliated Hospital of Xian Jiaotong University
-
-
Shandong
-
Jinan, Shandong, China, 250000
- Werving
- Shandong Provincial Hospital
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200025
- Werving
- Rui Jin Hospital Shanghai Jiao Tong University School of Medicine
-
-
Sichuan
-
Chengdu, Sichuan, China, 610071
- Werving
- Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China, 300020
- Werving
- Institute of Hematology and Hospital of Blood Disease
-
-
Yunnan
-
Kunming, Yunnan, China, 650032
- Werving
- First Affiliated Hospital of Kunming Medical University
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310002
- Werving
- The First Affiliated Hospital, Zhejiang University School of Medicinechengzhan
-
-
-
-
-
Deggendorf, Duitsland, 94469
- Werving
- Donauisar Klinikum Deggendorf Klinik Fur Onkologie Und Hamatologie
-
Frankfurt am Main, Duitsland, 60389
- Werving
- Centrum Fur Haematologie Und Onkologie Bethanien
-
Münster, Duitsland, 48153
- Werving
- Geho Munster
-
Straubing, Duitsland, 94315
- Werving
- Klinikum St Elisabeth Straubing Gmbh Mvz Klinikum Straubing Gmbh
-
-
-
-
-
Bordeaux, Frankrijk, 33076
- Werving
- Centre de Lutte Contre Le Cancer Institut Bergonie
-
ClermontFerrand, Frankrijk, 63100
- Werving
- Chu Clermont Ferrand Therapie Cellulaire and Hematolo
-
Le Mans, Frankrijk, 72037
- Werving
- Centre Hospitalier Le Mans
-
Lille, Frankrijk, 59000
- Werving
- Hopital Claude Huriez Chu Lille
-
Lyon, Frankrijk, 69373
- Werving
- Centre Leon Berard
-
Montpellier, Frankrijk, 34090
- Werving
- Chu Montpellier Hopital Saint Eloi
-
Toulouse, Frankrijk, 31100
- Werving
- Iuc Toulouse Oncopole
-
-
-
-
-
Bologna, Italië, 40138
- Werving
- Irccs Azienda Ospedaliero Universitaria Bologna
-
Florence, Italië, 50134
- Werving
- Aou Careggi, Servizio Sanitario Toscana
-
Milan, Italië, 20132
- Werving
- Ospedale San Raffaele
-
Milan, Italië, 20162
- Werving
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
-
Padova, Italië, 35128
- Werving
- Azienda Ospedaliera Di Padova
-
Roma, Italië, 00168
- Werving
- Fondazione Policlinico Universitario Agostino Gemelli
-
-
-
-
-
Almere Stad, Nederland, 1315 RA
- Werving
- Flevoziekenhuis
-
Dordrecht, Nederland, 3318 AT
- Werving
- Albert Schweitzer Ziekenhuis
-
Sgravenhage, Nederland, 2545 AA
- Werving
- Hagaziekenhuis
-
-
-
-
-
Auckland, Nieuw-Zeeland, 1023
- Werving
- Auckland City Hospital
-
Auckland, Nieuw-Zeeland, 0622
- Werving
- North Shore Hospital
-
Christchurch, Nieuw-Zeeland, 8011
- Werving
- Health New Zealand Canterbury
-
Dunedin, Nieuw-Zeeland, 9016
- Werving
- Dunedin Hospital
-
Wellington, Nieuw-Zeeland, 6021
- Werving
- Wellington Regional Hospital (Ccdhb)
-
-
-
-
-
Brzozów, Polen, 36-200
- Werving
- Szpital Specjalist W Brzozowie,Podkarpacki Osrodek Onkologiczny
-
Katowice, Polen, 40-519
- Werving
- Pratia Onkologia Katowice
-
Krakow, Polen, 30-727
- Werving
- Pratia McM Krakow
-
Lublin, Polen, 20-090
- Werving
- Uniwersytecki Szpital Kliniczny Nr 4 W Lublinie
-
Wroclaw, Polen, 50-367
- Werving
- Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu
-
-
-
-
-
Bucharest, Roemenië, 30171
- Werving
- Coltea Clinical Hospital
-
Bucureti, Roemenië, 022328
- Werving
- Institutul Clinic Fundeni
-
ClujNapoca, Roemenië, 400015
- Werving
- Institutul Oncologic Prof Dr Ion Chiricuta Cluj Napoca
-
-
-
-
-
Granada, Spanje, 18014
- Werving
- Hospital Universitario Virgen de Las Nieves
-
Madrid, Spanje, 28041
- Werving
- Hospital Universitario 12 de Octubre
-
Majadahonda, Spanje, 28222
- Werving
- Hospital Universitario Puerta de Hierro Majadahonda
-
Murcia, Spanje, 30120
- Werving
- Hospital Clinico Universitario Virgen de La Arrixaca
-
-
-
-
-
Brno, Tsjechië, 625 00
- Werving
- Fakultni Nemocnice Brno
-
Hradec Králové, Tsjechië, 500 03
- Werving
- Fakultni Nemocnice Hradec Kralove
-
Olomouc, Tsjechië, 77900
- Werving
- Fakultni Nemocnice Olomouc
-
Ostrava, Tsjechië, 708 00
- Werving
- Fakultni Nemocnice Ostrava
-
PLZE, Tsjechië, 323 00
- Werving
- Fakultni Nemocnice Plzen
-
Prague, Tsjechië, 10000
- Werving
- Vseobecna Fakultni Nemocnice V Praze
-
-
-
-
-
Birmingham, Verenigd Koninkrijk, B15 2TH
- Werving
- Queen Elizabeth Hospital
-
Bournemouth, Verenigd Koninkrijk, BH7 7DW
- Werving
- University Hospitals Dorset Royal Bournemouth Hospital
-
Leeds, Verenigd Koninkrijk, LS9 7TF
- Werving
- St Jamess University Hospital
-
London, Verenigd Koninkrijk, SE5 9RS
- Werving
- Kings College Hospital
-
Norwich, Verenigd Koninkrijk, NR4 7UY
- Werving
- Norfolk and Norwich University Hospitals Nhs Foundation Trust
-
-
-
-
California
-
Duarte, California, Verenigde Staten, 91010-3012
- Werving
- City of Hope National Medical Center
-
Orange, California, Verenigde Staten, 92868-3201
- Werving
- Chao Family Comprehensive Cancer Center
-
Palo Alto, California, Verenigde Staten, 94304-2205
- Werving
- Stanford Cancer Institute
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80012-5405
- Werving
- Rocky Mountain Cancer Centers (Williams) Usor
-
-
Florida
-
Jacksonville, Florida, Verenigde Staten, 32224-1865
- Werving
- Mayo Clinic Jacksonville
-
Miami, Florida, Verenigde Staten, 33140
- Werving
- Mount Sinai Medical Center Braman Comprehensive Cancer Center
-
Tampa, Florida, Verenigde Staten, 33612-9496
- Werving
- Moffitt Cancer Center
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60611
- Werving
- Northwestern University
-
Zion, Illinois, Verenigde Staten, 60099-2676
- Werving
- Midwestern Regional Medical Center
-
-
Louisiana
-
New Orleans, Louisiana, Verenigde Staten, 70121-2429
- Werving
- Ochsner Clinic Foundation
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02215-5418
- Werving
- Dana Farber Cancer Institute
-
-
Minnesota
-
Rochester, Minnesota, Verenigde Staten, 55905-0001
- Werving
- Mayo Clinic Rochester
-
-
Nebraska
-
Omaha, Nebraska, Verenigde Staten, 68198
- Werving
- University of Nebraska Medical Center
-
-
New York
-
New York, New York, Verenigde Staten, 10032
- Werving
- Columbia University Medical Center
-
-
North Carolina
-
Charlotte, North Carolina, Verenigde Staten, 28204-2990
- Werving
- Atrium Health Levine Cancer Institute (Lci)
-
Durham, North Carolina, Verenigde Staten, 27705-3976
- Werving
- Duke University Medical Center
-
-
Oregon
-
Eugene, Oregon, Verenigde Staten, 97401
- Werving
- Oncology Associates of Oregon Willamette Valley Cancer Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15232-1309
- Werving
- Upmc Hillman Cancer Center(Univ of Pittsburgh)
-
-
Texas
-
Tyler, Texas, Verenigde Staten, 75702-7522
- Werving
- Texas Oncology Tyler
-
-
Utah
-
Salt Lake City, Utah, Verenigde Staten, 84112-5550
- Werving
- Huntsman Cancer Institute
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98109-4433
- Werving
- Fred Hutchinson Cancer Research Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, Verenigde Staten, 53226-3522
- Werving
- Medical College of Wisconsin
-
-
-
-
Gyeonggi-do
-
Seongnam-si, Gyeonggi-do, Zuid -Korea, 13620
- Werving
- Seoul National University Bundang Hospital
-
-
Seoul Teugbyeolsi
-
SeochoGu, Seoul Teugbyeolsi, Zuid -Korea, 06591
- Werving
- The Catholic University of Korea, Seoul St Marys Hospital
-
SeodaemunGu, Seoul Teugbyeolsi, Zuid -Korea, 03722
- Werving
- Severance Hospital Yonsei University Health System
-
Seoul, Seoul Teugbyeolsi, Zuid -Korea, 03080
- Werving
- Seoul National University Hospital
-
SongpaGu, Seoul Teugbyeolsi, Zuid -Korea, 05505
- Werving
- Asan Medical Center
-
-
-
-
-
Stockholm, Zweden, 171 76
- Werving
- Karolinska Universitetssjukhuset Solna
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Treatment-naïve (TN) adults with confirmed diagnosis of CLL which requires treatment
- Eastern Cooperative Oncology Group (ECOG) score 0, 1, or 2
- Measurable disease by Computer Tomography/Magnetic Resonance Imaging
- Adequate bone marrow and organ function
Exclusion Criteria:
- Previous systemic treatment for CLL
- Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation
- Known central nervous system involvement
- History of confirmed progressive multifocal leukoencephalopathy (PML)
- Uncontrolled hypertension or clinically significant cardiovascular disease
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Arm A: Sonrotoclax plus Zanubrutinib
Participants will receive sonrotoclax and zanubrutinib for a fixed duration followed by observation. |
Administered orally.
Andere namen:
Administered orally.
Andere namen:
|
|
Actieve vergelijker: Arm B: Venetoclax plus Acalabrutinib
Participants will receive venetoclax and acalabrutinib for a fixed duration followed by observation. |
Administered orally.
Andere namen:
Administered orally.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Progression-Free Survival (PFS) as Determined by Independent Review Committee (IRC)
Tijdsspanne: Up to approximately 70 months
|
PFS is defined as the time from the date of randomization to the date of disease progression as determined by IRC or death due to any cause, whichever occurs first. |
Up to approximately 70 months
|
|
Rate of Undetectable Minimal Residual Disease at < 10^-4 sensitivity (uMRD4)
Tijdsspanne: Up to approximately 16 months
|
Rate of uMRD4 is defined as the percentage of participants that achieved uMRD4 measured in both peripheral blood (PB) and bone marrow aspirate (BMA) at the post-treatment follow-up visit (PTFU1) based on next generation sequencing (NGS). |
Up to approximately 16 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
PFS in High-Risk Participants
Tijdsspanne: Up to approximately 70 months
|
PFS is defined as the time from the date of randomization to the date of disease progression as determined by IRC or death due to any cause, whichever occurs first. |
Up to approximately 70 months
|
|
Overall Survival (OS)
Tijdsspanne: Up to approximately 70 months
|
OS is defined as the time from the date of randomization to the date of death due to any cause. |
Up to approximately 70 months
|
|
Overall Response Rate (ORR) as Determined by IRC
Tijdsspanne: Up to approximately 70 months
|
ORR is defined as the percentage of participants with a complete response (CR), complete response with incomplete hematopoietic recovery (CRi), nodal partial response (nPR), or partial response (PR), before disease progression, death, or the start of new anti-CLL treatment (whichever is earlier), as assessed by IRC. |
Up to approximately 70 months
|
|
Rate of Undetectable Minimal Residual Disease at < 10^-5 sensitivity (uMRD5)
Tijdsspanne: Up to approximately 16 months
|
Rate of uMRD5 is defined as the percentage of participants who achieved uMRD5 measured in both PB and BMA at the PTFU1 Visit based on NGS, before disease progression, death, or the start of new anti-CLL treatment (whichever is earlier). |
Up to approximately 16 months
|
|
Number of Participants with Adverse Events
Tijdsspanne: Up to approximately 70 months
|
Number of participants with treatment-emergent adverse events (TEAEs), adverse events of clinical interest, and serious adverse events (SAEs), including laboratory values, vital signs, and physical examination findings. |
Up to approximately 70 months
|
|
PFS Determined by Investigator Assessment
Tijdsspanne: Up to approximately 70 months
|
PFS is defined as the time from the date of randomization to the date of disease progression as determined by investigator or death due to any cause, whichever occurs first. |
Up to approximately 70 months
|
|
Complete Response Rate (CRR) by IRC and Investigator Assessment
Tijdsspanne: Up to approximately 70 months
|
CRR is defined as the percentage of participants with a CR or CRi before disease progression, death, or the start of new anti-CLL treatment (whichever is earlier). |
Up to approximately 70 months
|
|
ORR Determined by Investigator Assessment
Tijdsspanne: Up to approximately 70 months
|
ORR is defined as the percentage of participants with a complete response or partial response, before disease progression, death, or the start of new anti-CLL treatment (whichever is earlier), as assessed by investigator. |
Up to approximately 70 months
|
|
Duration of Response (DOR)
Tijdsspanne: Up to approximately 70 months
|
Duration of response (determined by both IRC and investigator assessment) is defined as the time from the first qualifying response (CR, CRi, nPR, or PR) until CLL progression or death. DOR analysis will only include responders. |
Up to approximately 70 months
|
|
Time to Next Treatment (TTNT)
Tijdsspanne: Up to approximately 70 months
|
TTNT is defined as the time from randomization to the start of the next treatment for CLL. |
Up to approximately 70 months
|
|
Change from Baseline in Score on European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL)-409 Questionnaire
Tijdsspanne: At baseline and up to approximately 70 months
|
Patient-reported symptoms of global health status (GHS), role functioning, and physical functioning, symptom burden and physical condition/fatigue will be measured using the European Organization for Research and Treatment of Cancer quality of life questionnaire EORTC IL-409 (an itemized version of [EORTC] quality of life questionnaire core 30 [QLQ-C30] and its CLL module CLL17). The EORTC-IL-409 consists of 17 questions answered on a 4-point scale where 1 = Not at all (best) to 4 = Very Much (worst) and 2 global health questions answered on a 7-point scale where 1 = Very poor (worst) to 7 = Excellent (best). Higher scores in GHS and functional scales and lower scores in symptom scales indicate better quality of life. |
At baseline and up to approximately 70 months
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Study Director, BeOne Medicines
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Pathologische processen
- Neoplasmata
- Chronische ziekte
- Ziekte attributen
- Ziekten van het immuunsysteem
- Neoplasmata per histologisch type
- Hematologische ziekten
- Lymfatische ziekten
- Lymfoproliferatieve aandoeningen
- Immunoproliferatieve aandoeningen
- Leukemie, B-cel
- Leukemie, Lymfoïde
- Leukemie
- Pathologische aandoeningen, tekenen en symptomen
- Hemische en lymfatische ziekten
- Leukemie, lymfatische, chronische, B-cel
- zanubrutinib
- venetoclax
- acalabrutinib
Andere studie-ID-nummers
- BGB-11417-304
- 2025-524366-21-00 (Ctis)
- 2025 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.
BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.
Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
IPD-tijdsbestek voor delen
See plan description
IPD-toegangscriteria voor delen
See plan description
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
- MVO
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .